Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04147052
Other study ID # IRB00116581
Secondary ID K23HD086154
Status Completed
Phase N/A
First received
Last updated
Start date September 3, 2021
Est. completion date April 20, 2022

Study information

Verified date May 2022
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sleep disturbance, especially insomnia (i.e., difficulty initiating and maintaining sleep), affects over half of people with MS. Cognitive behavioral strategies have been shown to improve sleep quantity and quality in several neurologic populations (e.g., traumatic brain injury, Parkinson's disease), and cognitive behavioral therapy for insomnia (CBT-I) is considered the first-line insomnia treatment for adults in the general population. Although cognitive behavioral interventions have historically been delivered in-person, a growing body of literature supports telephone- and internet-delivered approaches. However, more work is needed to understand the effects of internet-delivered CBT-I on patient-reported and objective outcomes. This study is a pilot randomized controlled trial to test the preliminary effects of iSLEEPms, a CBT-I-based online intervention with telephone support for individuals with MS. After completing a baseline assessment (Week 1), 90 participants with MS will be randomized (1:1) to four weeks (Weeks 2-5) of iSLEEPms (intervention group) or treatment as usual (TAU; control group), and complete post-treatment (Week 6) and follow-up (Week 12) assessments. iSLEEPms participants will complete daily sleep diary forms and weekly online educational modules. TAU participants will continue usual care without access to the iSLEEPms materials. The primary outcomes will be patient-reported and actigraphic measures of sleep quality and quantity. Secondary outcomes will be treatment satisfaction, adherence, and integrity (iSLEEPms group only). Exploratory outcomes will be fatigue symptoms, depression symptoms, and cognitive function.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date April 20, 2022
Est. primary completion date April 20, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Ages 18 and older - MS diagnosis56 of at least 1 year duration - Able to speak and read English - Sleep disturbance as indicated by an ISI score of at least 11 - Willingness to commit to a 4-week intervention and 12-week follow-up assessment Exclusion Criteria: - Neurological disorder other than MS - Hazardous alcohol use, as indicated by the Alcohol Use Disorders Identification Test (AUDIT-C) - Hazardous substance use, as indicated by the Drug Abuse Screening Test (DAST-10)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
iSLEEPms
Participants randomized to iSLEEPms complete daily online sleep diary forms and weekly online educational modules. Modules focus on typical elements of CBT-I, adapted for individuals with MS: education about sleep in MS, sleep restriction, and stimulus control; sleep hygiene and relaxation; and cognitive restructuring around sleep and coping with MS. Sleep diaries are scored each week, and feedback is provided to participants to guide adjustments to their recommended bedtimes and wake times. Telephone support is available to provide clarification around module content.

Locations

Country Name City State
United States Johns Hopkins University School of Medicine Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the Pittsburgh Sleep Quality Index (PSQI) total score The PSQI is a 9-item participant-reported measure that assesses sleep quality. Scores range from 0 to 21 points, with higher scores indicating poorer sleep quality. Scores = 5 are clinically significant. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Primary Change in the Insomnia Severity Index (ISI) total score The ISI is a 7-item participant-reported measure that assesses insomnia symptoms. Scores range from 0 to 28 points (each item is rated 0-4), with higher scores indicating greater insomnia. Scores = 11 are clinically significant. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Primary Change in actigraphic total sleep time (TST) Wrist actigraphy devices objectively assess TST, in minutes. TSTs < 360 min are considered clinically significant. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Primary Change in actigraphic sleep efficiency (SE) Wrist actigraphy devices objectively assess SE as a % of time asleep while in bed. SEs < 85% are considered clinically significant. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Primary Change in actigraphic sleep latency (SL) Wrist actigraphy devices objectively assess SL, in minutes. SLs > 30 min are considered clinically significant. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Primary Change in actigraphic wake after sleep onset (WASO) Wrist actigraphy devices objectively assess WASO, in minutes. WASOs > 30 min are considered clinically significant. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Secondary Change in the Modified Fatigue Impact Scale (MFIS) total score The MFIS is a 21-item participant-reported measure that assesses how much fatigue impacts physical, cognitive, and psychosocial functioning. Scores range from 0 to 84 (each item is rated 0-4), with higher scores indicating a greater impact of fatigue. Scores = 38 are clinically significant. The scale has three subscales (Physical, 9 items; Cognitive, 10 items; and Psychosocial, 2 items). Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Secondary Change in the Beck Depression Inventory - Fast Screen (BDI-FS) total score The BDI-FS is a 7-item participant-reported measure of depressive symptom severity. Scores range from 0 to 21 (each item rated 0-3), with higher scores indicating greater depressive symptom severity. Scores = 4 are clinically significant. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Secondary Change in the MS Neuropsychological Screening Questionnaire (MSNQ) total score The MSNQ is a 15-item participant-reported measure of subjective cognitive dysfunction. Scores range from 0 to 60 (each item rated 0-4), with higher scores indicating greater perceived cognitive dysfunction. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Secondary Change in the TestMyBrain Memorizing Words (MW) score TestMyBrain.org is an online platform that objectively assesses cognitive dysfunction. MW is a verbal paired associates test. Participants learn and memorize 25 word pairs and are asked to recall them after a delay. Higher scores indicate better verbal memory performance. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Secondary Change in the TestMyBrain Memorizing Pictures (MP) score TestMyBrain.org is an online platform that objectively assesses cognitive dysfunction. MP is a visual paired associates test. Participants learn and memorize 24 pictures pairs and are asked to recall them after a delay. Higher scores indicate better visual memory performance. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Secondary Change in the TestMyBrain Matching Shapes and Numbers (MSN) score TestMyBrain.org is an online platform that objectively assesses cognitive dysfunction. MSN is a speeded digit-symbol coding task. Participants use a key provided on the screen to quickly match 9 unique symbols with their correctly paired digits as quickly as possible. Higher scores indicate faster processing speed. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Secondary Change in the TestMyBrain Fast Choices (FC) score TestMyBrain.org is an online platform that objectively assesses cognitive dysfunction. FC is a choice reaction time test. Participants view arrows and quickly judge their direction. Higher scores indicate faster processing speed. Baseline (Week 1), Post-intervention (Week 6), and Follow-up (Week 12)
Secondary Treatment Satisfaction Scale (TSS) total score (iSLEEPms group only) The TSS a 7-item participant-reported measure adapted from the Consumer Report Treatment Satisfaction Scale to assess satisfaction with iSLEEPms. The 7 items (each item rated 1 to 5) are averaged to calculate a total score, with higher scores indicating greater symptom improvement during the iSLEEPms program. Post-intervention (Week 6)
Secondary iSLEEPms treatment adherence (iSLEEPMS group only) Treatment adherence will be assessed based on completion of each of the four weekly iSLEEPms modules, including completion of the online daily sleep diary form and weekly module. A total score will be determined based on the percentage of diary forms and weekly modules completed over four weeks. Post-intervention (Week 6)
Secondary iSLEEPms treatment integrity (iSLEEPMS group only) Treatment integrity will be assessed based on coverage of coverage of 17 CBT-I elements, adapted from the Treatment Components Adherence Scale. A total score will be determined based on the percentage of elements covered over the four-week iSLEEPms intervention. Post-intervention (Weeks 6)
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis